S-1: Palisade Bio Seeks $5 Million in Public Offering to Advance IBD Treatment

Palisade Bio is launching a public offering of common stock and pre-funded warrants to raise capital for its PALI-2108 clinical trial and other research initiatives.

Summary

• Palisade Bio, a biopharmaceutical company, has filed a Form S-1 registration statement for a proposed public offering.
• The offering includes shares of common stock and pre-funded warrants to purchase common stock, aiming to raise approximately $5 million.
• The company intends to use the net proceeds primarily for its Phase 1 clinical trial of PALI-2108, pre-clinical studies, research and development, and working capital.
• The underwriters have a 45-day option to purchase additional shares to cover over-allotments.
• The offering also includes representative warrants to the underwriters to purchase up to 6% of the shares sold.
• Palisade Bio's common stock is listed on The Nasdaq Capital Market under the symbol PALI.
• The company is currently enrolling patients in a Phase 1 clinical trial of PALI-2108 in Canada and plans to file an IND with the FDA in 2025 to commence clinical trials in the United States.
• PALI-2108 is being developed as a treatment for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).

Sentiment

Score: 6

Explanation: The sentiment is neutral. The announcement is a standard capital raise to fund ongoing operations. While the clinical trial progress is positive, the offering itself presents dilution risks.

Positives

• The offering will provide capital to advance the clinical development of PALI-2108, a promising treatment for IBD.
• The company has received a No Objection Letter (NOL) from Health Canada for its Phase 1 clinical study of PALI-2108.
• The company has completed the screening of its first cohort of normal healthy volunteers and is proceeding with its planned Phase 1 clinical study, which will be conducted in Canada.
• The company anticipates that the Phase 1 clinical study will commence during the fourth quarter of 2024.
• The company anticipates filing an Investigational New Drug Application (IND) with the United States Food and Drug Administration (FDA) during 2025.
• The company anticipates commencing clinical trials of PALI-2108 in the United States during the second half of 2025.

Negatives

• The offering will dilute existing shareholders' ownership.
• The company has broad discretion in how it uses the proceeds of the offering.
• The market price of the company's common stock may fluctuate significantly.
• There is no established trading market for the pre-funded warrants being offered.

Risks

• The company may not use the proceeds of the offering effectively.
• The company's stock price may fluctuate after the offering.
• Investors will experience immediate and substantial dilution as a result of the offering.
• Future sales of a significant number of the company's shares could depress the market price.
• There is no public market for the pre-funded warrants being offered.
• The company's business depends on the successful clinical development, regulatory approval, and commercialization of its therapeutic compounds, including its lead asset PALI-2108.
• The company depends on its license agreement with Giiant to permit it to use patents and patent applications relating to PALI-2108.

Future Outlook

The company plans to use the net proceeds from this offering primarily for its recently approved Phase 1 clinical trial of PALI-2108, pre-clinical studies, research and development, and working capital. The company anticipates filing an Investigational New Drug Application (IND) with the United States Food and Drug Administration (FDA) during 2025 and commencing clinical trials of PALI-2108 in the United States during the second half of 2025.

Industry Context

The market for ulcerative colitis treatments was valued at approximately $7.3 billion in 2021 and is expected to grow at a CAGR of approximately 2.78% from 2021 to 2031. The global market for Crohn's disease treatments was valued at $13.3 billion in 2023 and is projected to grow at a CAGR of 4% from 2024 to 2032. Palisade Bio is positioning itself to address a significant unmet need in the treatment of IBD.

Comparison to Industry Standards

• PDE4 inhibitors are an established class of drugs for inflammatory conditions, but they often suffer from systemic side effects.
• Palisade Bio's PALI-2108 aims to overcome these limitations by providing localized delivery of the PDE4 inhibitor to the colon.
• Competitors in the IBD space include companies developing both small molecule and biologic therapies, such as Takeda (Entyvio), AbbVie (Humira, Rinvoq), and Janssen (Stelara).
• The company's precision medicine approach, using biomarkers to identify potential responders, is similar to strategies employed by other companies in the pharmaceutical industry to improve clinical trial outcomes and personalize treatment.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• Employees will benefit from the continued funding of research and development activities.
• Patients with IBD may benefit from the development of a new treatment option.

Next Steps

• Complete the public offering.
• Commence the Phase 1 clinical study of PALI-2108 in Canada.
• File an Investigational New Drug Application (IND) with the FDA.
• Commence clinical trials of PALI-2108 in the United States.

Key Dates

Keywords

public offering, PALI-2108, inflammatory bowel disease, pre-funded warrants, clinical trial, Palisade Bio, IBD, UC, CD